Peter John Murray
Plus aucun poste en cours
Profil
Peter John Murray was the founder of RespiVert Ltd.
which was founded in 2006, where he held the title of Chemistry Director.
He worked as a Principal at GSK Plc and as Vice President-Discovery Sciences at Prosidion Ltd.
He also worked as a Principal at OSI Pharmaceuticals (UK) Ltd.
from 2009 to 2012.
Dr. Murray earned a doctorate degree from Imperial College London in 1986.
Anciens postes connus de Peter John Murray
| Sociétés | Poste | Fin |
|---|---|---|
Prosidion Ltd.
 Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Corporate Officer/Principal | - |
RespiVert Ltd.
 RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Fondateur | - |
| GSK PLC | Corporate Officer/Principal | - |
| OSI Pharmaceuticals (UK) Ltd. | Corporate Officer/Principal | - |
Formation de Peter John Murray
| Imperial College London | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
RespiVert Ltd.
RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Distribution Services |
| OSI Pharmaceuticals (UK) Ltd. |
